{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:19:21Z","timestamp":1791533961986,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01788-1","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:03:11Z","timestamp":1782698591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-PD-1 Combinations: Triplets and Beyond"],"prefix":"10.1007","volume":"28","author":[{"given":"Claudia","family":"Trojaniello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella Lucia","family":"Marretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Arianna","family":"Facchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"33","key":"1788_CR1","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1200\/JCO.20.00995","volume":"38","author":"C Robert","year":"2020","unstructured":"Robert C, Ribas A, Schachter J, et al. Five-Year Outcomes with Nivolumab in Patients with Wild-Type BRAF Advanced Melanoma: Results from the Phase III CheckMate 066 Trial. J Clin Oncol. 2020;38(33):3937\u201346. https:\/\/doi.org\/10.1200\/JCO.20.00995.","journal-title":"J Clin Oncol"},{"key":"1788_CR2","doi-asserted-by":"crossref","unstructured":"Long GV, Carlino MS, McNeil C, Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol., Chiarion-Sileni V, Rutkowski P,CheckMate 067 Investigators. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2025;392(1):11\u201322. doi:10.1056\/NEJMoa2407417. \u2022Lipson, Hodi EJ et al. FS, Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. Eur J Cancer. 2025;225:115547. doi:10.1016\/j.ejca.2025.115547.","DOI":"10.1016\/j.ejca.2025.115547"},{"issue":"1","key":"1788_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. CheckMate 067 Investigators. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2025;392(1):11\u201322. . https:\/\/doi.org\/10.1056\/NEJMoa2407417","journal-title":"N Engl J Med"},{"key":"1788_CR27","doi-asserted-by":"publisher","unstructured":"Lipson EJ, Hodi FS, et al. Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. Eur J Cancer. 2025;225:115547. . https:\/\/doi.org\/10.1016\/j.ejca.2025.115547","DOI":"10.1016\/j.ejca.2025.115547"},{"key":"1788_CR3","doi-asserted-by":"crossref","unstructured":"Tawbi HA, Hodi FS, Lipson EJ, et al. Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047. J Clin Oncol. 2024;42(\u2026 JCO.24.01124. \u2022Ascierto PA, Dummer R, Gaudy-Marqueste C, et al. Efficacy and safety of triplet nivolumab,relatlimab, and ipilimumab (NIVO+RELA\u2009+\u2009IPI) in advanced melanoma: Results from RELATIVITY-048.J Clin Oncol. 2024;42(16_suppl):9504. doi:10.1200\/JCO.2024.42.16_suppl.9504.","DOI":"10.1200\/JCO.2024.42.16_suppl.9504"},{"issue":"16suppl","key":"1788_CR28","doi-asserted-by":"publisher","first-page":"9504","DOI":"10.1200\/JCO.2024.42.16_suppl.9504","volume":"42","author":"PA Ascierto","year":"2024","unstructured":"Ascierto PA, Dummer R, Gaudy-Marqueste C, et al. Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO+RELA+IPI) in advanced melanoma: Results from RELATIVITY-048. J Clin Oncol. 2024;42(16suppl):9504. . https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9504","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"1788_CR4","doi-asserted-by":"publisher","first-page":"S923","DOI":"10.1016\/j.annonc.2022.07.948","volume":"33","author":"N Abdel-Wahab","year":"2022","unstructured":"Abdel-Wahab N, Montazari EJ, Spillson C, et al. Phase II: Tocilizumab plus ipilimumab and nivolumab in metastatic melanoma\u2014safety and efficacy. Ann Oncol. 2022;33(Suppl):S923.","journal-title":"Ann Oncol"},{"issue":"16suppl","key":"1788_CR5","doi-asserted-by":"publisher","first-page":"9538","DOI":"10.1200\/JCO.2024.42.16_suppl.9538","volume":"42","author":"JS Weber","year":"2024","unstructured":"Weber JS, Puranik A, Mitzutan T, et al. IL-6R blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma. J Clin Oncol. 2024;42(16suppl):9538.","journal-title":"J Clin Oncol"},{"key":"1788_CR6","doi-asserted-by":"crossref","unstructured":"Diab A 169TiP: Tocilizumab, ipilimumab, and nivolumab for advanced melanoma\/NSCLC\/urothelial carcinoma\u2014trial in progress. Ann Oncol., \u2022Anouti B, McVay K, Abraham M, Johnson DH et al. Weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: clinical outcomes and biomarker analysis. J Clin Oncol. 2024;42(16_suppl):9553.","DOI":"10.1200\/JCO.2024.42.16_suppl.9553"},{"issue":"16suppl","key":"1788_CR29","doi-asserted-by":"publisher","first-page":"9553","DOI":"10.1200\/JCO.2024.42.16_suppl.9553","volume":"42","author":"B Anouti","year":"2024","unstructured":"Anouti B, McVay K, Abraham M, Johnson DH, et al. Weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: clinical outcomes and biomarker analysis. J Clin Oncol. 2024;42(16suppl):9553.","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"1788_CR7","doi-asserted-by":"publisher","first-page":"9510","DOI":"10.1200\/JCO.2025.43.16_suppl.9510","volume":"43","author":"JM Mehnert","year":"2025","unstructured":"Mehnert JM, Mehmi I, Goldberg JD, et al. A phase II study of the interleukin-6 (IL-6) receptor blocking antibody sarilumab (Sari) in combination with ipilimumab (Ipi), nivolumab (Nivo) and relatlimab (Rela) in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2025;43(suppl 16):9510.","journal-title":"J Clin Oncol"},{"key":"1788_CR8","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1084\/jem.20051848","volume":"203","author":"H Sumimoto","year":"2006","unstructured":"Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med. 2006;203:1651\u20136.","journal-title":"J Exp Med"},{"key":"1788_CR9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00262-012-1389-z","volume":"62","author":"PA Ott","year":"2013","unstructured":"Ott PA, Henry T, Baranda SJ, et al. Inhibition of both BRAF and MEK in BRAF(V600E) melanoma restores compromised dendritic-cell function. Cancer Immunol Immunother. 2013;62:811\u201322.","journal-title":"Cancer Immunol Immunother"},{"key":"1788_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.phrs.2018.08.019","volume":"136","author":"M Kuske","year":"2018","unstructured":"Kuske M, Westphal D, Wehner R, et al. Immunomodulatory effects of BRAF and MEK inhibitors: implications for melanoma therapy. Pharmacol Res. 2018;136:151\u20139.","journal-title":"Pharmacol Res"},{"key":"1788_CR11","doi-asserted-by":"publisher","first-page":"e22890","DOI":"10.4161\/onci.22890","volume":"2","author":"B Sapkota","year":"2013","unstructured":"Sapkota B, Hill CE, Pollack BP. Vemurafenib enhances MHC induction in BRAF(V600E) melanoma cells. Oncoimmunology. 2013;2:e22890.","journal-title":"Oncoimmunology"},{"key":"1788_CR12","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","volume":"70","author":"A Boni","year":"2010","unstructured":"Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma. Cancer Res. 2010;70:5213\u20139.","journal-title":"Cancer Res"},{"key":"1788_CR13","doi-asserted-by":"publisher","first-page":"e1468955","DOI":"10.1080\/2162402X.2018.1468955","volume":"7","author":"PA Ascierto","year":"2018","unstructured":"Ascierto PA, Dummer R. Immunological effects of BRAF\u2009+\u2009MEK inhibition. Oncoimmunology. 2018;7:e1468955.","journal-title":"Oncoimmunology"},{"key":"1788_CR14","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","volume":"18","author":"JS Wilmott","year":"2012","unstructured":"Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18:1386\u201394.","journal-title":"Clin Cancer Res"},{"key":"1788_CR15","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","volume":"162","author":"W Hugo","year":"2015","unstructured":"Hugo W, Shi H, Sun L, et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell. 2015;162:1271\u201385.","journal-title":"Cell"},{"key":"1788_CR16","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","volume":"25","author":"A Ribas","year":"2019","unstructured":"Ribas A, Lawrence D, Atkinson V, et al. Combined BRAF and MEK inhibition with PD-1 blockade in BRAF-mutant melanoma. Nat Med. 2019;25:936\u201340.","journal-title":"Nat Med"},{"key":"1788_CR17","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","volume":"25","author":"PA Ascierto","year":"2019","unstructured":"Ascierto PA, Ferrucci PF, Fisher R, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019;25:941\u20136.","journal-title":"Nat Med"},{"key":"1788_CR18","doi-asserted-by":"publisher","first-page":"e001806","DOI":"10.1136\/jitc-2020-001806","volume":"8","author":"PF Ferrucci","year":"2020","unstructured":"Ferrucci PF, Di Giacomo AM, Del Vecchio M, et al. KEYNOTE-022 part 3: pembrolizumab\u2009+\u2009dabrafenib\u2009+\u2009trametinib randomized phase 2. J Immunother Cancer. 2020;8:e001806.","journal-title":"J Immunother Cancer"},{"key":"1788_CR19","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib (IMspire150). Lancet. 2020;395:1835\u201344.","journal-title":"Lancet"},{"key":"1788_CR20","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-020-1082-2","volume":"26","author":"R Dummer","year":"2020","unstructured":"Dummer R, Lebb\u00e9 C, Atkinson V, et al. Combined PD-1, BRAF and MEK inhibition: COMBI-i safety run-in and biomarker cohorts. Nat Med. 2020;26:1557\u201363.","journal-title":"Nat Med"},{"key":"1788_CR21","doi-asserted-by":"publisher","first-page":"e004226","DOI":"10.1136\/jitc-2021-004226","volume":"10","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Robert C, Brase JC, et al. Spartalizumab or placebo with dabrafenib\u2009+\u2009trametinib: COMBI-i exploratory biomarker analyses. J Immunother Cancer. 2022;10:e004226.","journal-title":"J Immunother Cancer"},{"key":"1788_CR22","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.21.01601","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer R, Long GV, Robert C, et al. Randomized phase III spartalizumab\u2009+\u2009dabrafenib\u2009+\u2009trametinib. J Clin Oncol. 2022;40:1428\u201338.","journal-title":"J Clin Oncol"},{"issue":"15suppl","key":"1788_CR23","doi-asserted-by":"publisher","first-page":"9520","DOI":"10.1200\/JCO.2021.39.15_suppl.9520","volume":"39","author":"EM Burton","year":"2021","unstructured":"Burton EM, Amaria RN, Glitza IC, et al. Phase II TRIDeNT (nivolumab\u2009+\u2009dabrafenib\u2009+\u2009trametinib) in PD-1-na\u00efve\/refractory BRAF-mutant melanoma. J Clin Oncol. 2021;39(15suppl):9520.","journal-title":"J Clin Oncol"},{"key":"1788_CR24","doi-asserted-by":"publisher","first-page":"115070","DOI":"10.1016\/j.ejca.2024.115070","volume":"213","author":"O Dudnichenko","year":"2024","unstructured":"Dudnichenko O, Penkov K, McKean M, et al. First-line encorafenib\u2009+\u2009binimetinib\u2009+\u2009pembrolizumab (STARBOARD) safety lead-in. Eur J Cancer. 2024;213:115070.","journal-title":"Eur J Cancer"},{"key":"1788_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2021.09.011","volume":"158","author":"L Zimmer","year":"2021","unstructured":"Zimmer L, Livingstone E, Krackhardt A, et al. Pembrolizumab\u2009+\u2009encorafenib\u2009+\u2009binimetinib (IMMU-TARGET) phase I: safety and tolerability. Eur J Cancer. 2021;158:72\u201384.","journal-title":"Eur J Cancer"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01788-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01788-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01788-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:04:17Z","timestamp":1782741857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01788-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1788"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01788-1","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"All reported studies with human subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}],"article-number":"70"}}